Speaker Credentials
OMS-II
College
Dr. Kiran C. Patel College of Osteopathic Medicine, DO
Medical Specialty
Internal Medicine
Format
Poster
Start Date
November 2024
End Date
November 2024
Track
3
Abstract
Objective: This review examines tirzepatide, a GLP-1 agonist, to treat liver diseases like nonalcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH). Background: Initially FDA-approved for type 2 diabetes and obesity, tirzepatide shows potential benefits for liver diseases. Clinical studies are evaluating its hepatoprotective properties in NAFLD and MASH. Methods: The review includes primary studies and ongoing clinical trials from the last five years involving patients over 18 diagnosed with NAFLD or MASH. Search terms included tirzepatide, GLP1s, MASH, NAFLD, fibrosis, and albumin. Results: A clinical study demonstrated that after 52 weeks of tirzepatide treatment, MASH resolution without worsening fibrosis occurred in all experimental groups at statistically higher rates than those receiving placebos. Over 50% of participants in treatment groups demonstrated 1-stage or greater improvement of fibrosis, compared to less than 30% of participants in placebo groups. NAFLD activity scores decreased by at least one point in two or more categories for 72-78% of participants in treatment, compared to only 37% in the placebo group. Biomarkers of liver damage decreased in tirzepatide groups, and two studies found increased hepatoprotective albumin. tirzepatide significantly lowered ALT levels more effectively than dulaglutide compared to other medications. NCT04166773 is the ongoing clinical trial evaluating tirzepatide in participants with Nonalcoholic Steatohepatitis (NASH). Conclusion: Current literature suggests that tirzepatide has a promising role in hepatoprotection and liver dysfunction management. However, gaps remain regarding its long-term impacts and the mechanisms behind its hepatic benefits, necessitating further research.
Included in
Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review
Objective: This review examines tirzepatide, a GLP-1 agonist, to treat liver diseases like nonalcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH). Background: Initially FDA-approved for type 2 diabetes and obesity, tirzepatide shows potential benefits for liver diseases. Clinical studies are evaluating its hepatoprotective properties in NAFLD and MASH. Methods: The review includes primary studies and ongoing clinical trials from the last five years involving patients over 18 diagnosed with NAFLD or MASH. Search terms included tirzepatide, GLP1s, MASH, NAFLD, fibrosis, and albumin. Results: A clinical study demonstrated that after 52 weeks of tirzepatide treatment, MASH resolution without worsening fibrosis occurred in all experimental groups at statistically higher rates than those receiving placebos. Over 50% of participants in treatment groups demonstrated 1-stage or greater improvement of fibrosis, compared to less than 30% of participants in placebo groups. NAFLD activity scores decreased by at least one point in two or more categories for 72-78% of participants in treatment, compared to only 37% in the placebo group. Biomarkers of liver damage decreased in tirzepatide groups, and two studies found increased hepatoprotective albumin. tirzepatide significantly lowered ALT levels more effectively than dulaglutide compared to other medications. NCT04166773 is the ongoing clinical trial evaluating tirzepatide in participants with Nonalcoholic Steatohepatitis (NASH). Conclusion: Current literature suggests that tirzepatide has a promising role in hepatoprotection and liver dysfunction management. However, gaps remain regarding its long-term impacts and the mechanisms behind its hepatic benefits, necessitating further research.